神经精神药理英文课件：Experimental Therapies for Alzheimer’s Disease.pptVIP

* Janssen PCP Core T1 Syllabus WO: 2749 * * * What’s Holding Us Back? Too many subjects, too much time too much money using clinical endpoints Insufficient evidence to support the “qualification for use” of AD biomarkers as surrogate endpoints The safety tolerability data needed to evaluate investigational AD-modifying treatments in presymptomatic AD trials Biomarkers of AD Progression Pathology* Structural MRI measurements FDG PET measurements Fibrillar Aβ PET measurements CSF Aβ42, alone or in combination with t-tau or p-tau levels *in both the symptomatic presymptomatic stages of AD